 | |
| Clinical data | |
|---|---|
| Trade names | Ultravist |
| AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
|
Pregnancy category |
|
|
Routes of administration | Intravascular |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | ~1% |
| Metabolism | None |
| Elimination half-life | 2 hours |
| Excretion | Kidneys |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.070.330 |
| Chemical and physical data | |
| Formula | C18H24I3N3O8 |
| Molar mass | 791.116 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
 
(what is this?)
(verify) | |
Iopromide is an iodinated contrast medium for X-ray imaging. It is marketed under the name Ultravist which is produced by Bayer Healthcare. It is a low osmolar, non-ionic contrast agent for intravascular use; i.e., it is injected into blood vessels. [2]
It is commonly used in radiographic studies such as intravenous urograms, brain computer tomography (CT) [2] and CT pulmonary angiograms (CTPAs).
Medical uses
The radiocontrast agent is given intravenously in computed tomography (CT) scans, angiography and excretory urography. [3]
Contraindications
Iopromide use is contraindicated in myelography, cerebral ventriculography and cisternography procedures. It is also contraindicated in those with hyperthyroidism, or with known allergy to the drug. [4]
Iopromide is also contraindicated in children with prolonged fasting, fluid restriction, on laxative, or dehydration as it can cause renal failure. [4]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ a b Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Ultravist 300 mg J/ml-Infusionsflaschen.
- ^ "Prescribing information - Ultravist" (PDF). Bayer Healthcare pharmaceuticals. Archived from the original (PDF) on 10 April 2021.
- ^ a b "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ULTRAVIST® Iopromide Injection" (PDF). Bayer Healthcare Pharmaceuticals. Archived from the original (PDF) on 27 October 2021. Retrieved 16 April 2024.
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| Trade names | Ultravist |
| AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
|
Pregnancy category |
|
|
Routes of administration | Intravascular |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | ~1% |
| Metabolism | None |
| Elimination half-life | 2 hours |
| Excretion | Kidneys |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.070.330 |
| Chemical and physical data | |
| Formula | C18H24I3N3O8 |
| Molar mass | 791.116 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
|
(what is this?)
(verify) | |
Iopromide is an iodinated contrast medium for X-ray imaging. It is marketed under the name Ultravist which is produced by Bayer Healthcare. It is a low osmolar, non-ionic contrast agent for intravascular use; i.e., it is injected into blood vessels. [2]
It is commonly used in radiographic studies such as intravenous urograms, brain computer tomography (CT) [2] and CT pulmonary angiograms (CTPAs).
Medical uses
The radiocontrast agent is given intravenously in computed tomography (CT) scans, angiography and excretory urography. [3]
Contraindications
Iopromide use is contraindicated in myelography, cerebral ventriculography and cisternography procedures. It is also contraindicated in those with hyperthyroidism, or with known allergy to the drug. [4]
Iopromide is also contraindicated in children with prolonged fasting, fluid restriction, on laxative, or dehydration as it can cause renal failure. [4]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ a b Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Ultravist 300 mg J/ml-Infusionsflaschen.
- ^ "Prescribing information - Ultravist" (PDF). Bayer Healthcare pharmaceuticals. Archived from the original (PDF) on 10 April 2021.
- ^ a b "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ULTRAVIST® Iopromide Injection" (PDF). Bayer Healthcare Pharmaceuticals. Archived from the original (PDF) on 27 October 2021. Retrieved 16 April 2024.
External links
|
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |